Study design and rationale for the Olpasiran trials of Cardiovascular Events And lipoproteiN(a) reduction-DOSE finding study (OCEAN(a)-DOSE)

• Published in: The American heart journal Vol. 251; pp. 61 - 69
• Main Authors: O'Donoghue, Michelle L., G． López, J. Antonio, Knusel, Beat, Gencer, Baris, Wang, Huei, Wu, You, Kassahun, Helina, Sabatine, Marc S.
• Format: Journal Article
• Language: English
• Published: Philadelphia Elsevier Inc 01.09.2022; Elsevier Limited
• Subjects: Apolipoproteins; Arteriosclerosis; Atherosclerosis; Cardiovascular disease; Cardiovascular diseases; Cerebrovascular disease; Clinical trials; Design; Dosage; Drug dosages; Health risks; Hepatocytes; Lipoproteins; Placebos; Plasma; Reduction; Risk analysis; Risk factors; siRNA; Japan

Data support lipoprotein(a) (Lp[Lp(a)]) being a risk factor for atherosclerotic cardiovascular disease (ASCVD). Olpasiran is a small interfering RNA molecule that markedly reduces Lp(a) production in hepatocytes. The Olpasiran trials of Cardiovascular Events And lipoproteiN(a) reduction-DOSE finding...